DBV: EPIT Prevents Further Allergies By Influencing Natural History Of Allergy

(RTTNews) - DBV Technologies, (DBVT), a clinical-stage specialty biopharmaceutical company, announced Monday the publication of a set of experimental data in the Journal of Allergy and Clinical Immunology or JACI demonstrating that early treatment with Epicutaneous Immunotherapy or EPIT using Viaskin may induce protection from sensitization to other allergens.

The pre-clinical data demonstrate that treatment with EPIT could prevent further allergies by influencing the natural history of allergy via a Treg-dependent mechanism. This protective response induced by EPIT is sustained after the end of treatment.

Pierre-Henri Benhamou, Chairman and CEO of DBV Technologies, said, "These new data gives us a new perspective for the treatment of food allergy. This publication shows us the scope of applications for EPIT in allergy, especially in young children, and we will continue to work on strengthening our understanding of EPIT's mechanism of action with Viaskin. If confirmed in Humans, this treatment could have the potential to fundamentally transform the management of the allergic disease."